Intelect Medical expands clinical trials for its deep brain stimulation (DBS)
Intelect Medical, Inc., a Cleveland Clinic-founded company that develops implantable neuromodulation systems for brain injury recovery, plans to expand clinical feasibility trials for its investigational traumatic brain injury (TBI) recovery and stroke recovery therapies using deep brain stimulation (DBS) with funding from Boston Scientific and Greatbatch. "Stroke and traumatic brain injury affect millions of people," said Vincent Owens, President and Chief Executive Officer, Intelect Medical. "The funding will allow us to continue our applied research and clinical studies of DBS therapies and provide therapeutic options to help patients recover from stroke and TBI disabilities." Ali Rezai, M.D., Director of Cleveland Clinic's Center for Neurological Restoration further adds, "It is gratifying to see our technology and therapies move from the lab and closer to patient care. Our therapies present a significant opportunity to improve treatment options for stroke and TBI recovery." Both stroke and TBI are leading causes of serious, long-term disability worldwide. According to the National Institute for Neurological Disorders and Stroke, these two disabilities combined have an annual incidence of 2.2 million, while creating in excess of $115 billion in direct healthcare costs annually. Four million people in the United States are survivors of stroke and more than 5 million suffer from TBI disabilities.
